Stock ANGO ANGIODYNAMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Real-time Estimate Cboe BZX
Other stock markets
 09:50:55 2024-05-24 am EDT 		5-day change 1st Jan Change
6.05 USD -1.14% Intraday chart for AngioDynamics, Inc. +0.83% -22.32%
May. 21 AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System MT
May. 06 AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV) CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System
MT
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
BU
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
BU
AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV)
CI
North American Morning Briefing : Inflation Data, -2-
DJ
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results, Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
AQ
AngioDynamics Receives 510(k) Clearance for AlphaVac F18 System in Treatment of PE
AQ
Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target
MT
AngioDynamics Shares Jump After Fiscal Q3 Results, FDA Clearance For Device
MT
AngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 System
DJ
Transcript : AngioDynamics, Inc., Q3 2024 Earnings Call, Apr 04, 2024
AngioDynamics Gets FDA Clearance For Pulmonary Embolism Treatment
DJ
AngioDynamics: Fiscal Q3 Earnings Snapshot
AQ
Earnings Flash (ANGO) ANGIODYNAMICS Reports Q3 Revenue $66M
MT
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
BU
AngioDynamics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024
CI
AngioDynamics, Inc. Reports Consolidated Goodwill Impairment for Third Quarter Ended February 29, 2024
CI
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024
CI
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
BU
AngioDynamics, Inc. Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANGO Stock
  4. News AngioDynamics, Inc.